Dr Vyom Sharma
@drvyom.bsky.social
Australian GP #medsky
Broadcaster
Magic Creator at DARK CUBE
www.vyomsharma.com.au
I miss the racism on twitter.
Broadcaster
Magic Creator at DARK CUBE
www.vyomsharma.com.au
I miss the racism on twitter.
More research is needed.
August 10, 2025 at 7:04 AM
More research is needed.
Am I going to end with "more research is needed?"
August 10, 2025 at 7:04 AM
Am I going to end with "more research is needed?"
A drop of 3mm Hg - considering the trial only ran effectively for a month, and the potential population level impacts - I think that's quite impressive.
August 10, 2025 at 7:04 AM
A drop of 3mm Hg - considering the trial only ran effectively for a month, and the potential population level impacts - I think that's quite impressive.
- the CI for this finding from this > 120 mm Hg subgroup comes awfully close to 0 (-5.9 to -0.1)
- effect size of SBP reducing by 3mm Hg is small. We expect meds to make at least 5 mm Hg difference.
But...
- effect size of SBP reducing by 3mm Hg is small. We expect meds to make at least 5 mm Hg difference.
But...
August 10, 2025 at 7:04 AM
- the CI for this finding from this > 120 mm Hg subgroup comes awfully close to 0 (-5.9 to -0.1)
- effect size of SBP reducing by 3mm Hg is small. We expect meds to make at least 5 mm Hg difference.
But...
- effect size of SBP reducing by 3mm Hg is small. We expect meds to make at least 5 mm Hg difference.
But...
Link: www.jacc.org/doi/10.1016/...
Weaknesses:
- main outcome, null trial slightly underpowered
- the 3mm Hg reduction was in a subgroup analysis (pre-specified though which is good)
- not clear if the study was powered adequately for this subgroup analysis
Weaknesses:
- main outcome, null trial slightly underpowered
- the 3mm Hg reduction was in a subgroup analysis (pre-specified though which is good)
- not clear if the study was powered adequately for this subgroup analysis
www.jacc.org
August 10, 2025 at 7:04 AM
Link: www.jacc.org/doi/10.1016/...
Weaknesses:
- main outcome, null trial slightly underpowered
- the 3mm Hg reduction was in a subgroup analysis (pre-specified though which is good)
- not clear if the study was powered adequately for this subgroup analysis
Weaknesses:
- main outcome, null trial slightly underpowered
- the 3mm Hg reduction was in a subgroup analysis (pre-specified though which is good)
- not clear if the study was powered adequately for this subgroup analysis
Yes, the GI one is the most convincing claim on that list for being a global trend.
Sorry to hear about your ca! I sincerely hope it is being managed well and turns out ok
Sorry to hear about your ca! I sincerely hope it is being managed well and turns out ok
July 10, 2025 at 12:32 PM
Yes, the GI one is the most convincing claim on that list for being a global trend.
Sorry to hear about your ca! I sincerely hope it is being managed well and turns out ok
Sorry to hear about your ca! I sincerely hope it is being managed well and turns out ok
Thanks for that link. good read.
July 8, 2025 at 9:42 PM
Thanks for that link. good read.
I think there are many environmental concerns like youv'e suggested. But I think that first, we need to be more certain that there truly is an increase in cancer in younger people.
And what I'm saying here is that it's not obvious to me that we know this for sure.
And what I'm saying here is that it's not obvious to me that we know this for sure.
July 8, 2025 at 11:16 AM
I think there are many environmental concerns like youv'e suggested. But I think that first, we need to be more certain that there truly is an increase in cancer in younger people.
And what I'm saying here is that it's not obvious to me that we know this for sure.
And what I'm saying here is that it's not obvious to me that we know this for sure.
